Fortrea (FTRE) Form 4: 11,312 RSUs Converted; 4,886 Shares Sold at $8.01
Rhea-AI Filing Summary
Jill G. McConnell, Chief Financial Officer of Fortrea Holdings Inc. (FTRE), reported vesting and related sales of equity awards. On 08/18/2025 11,312 Restricted Stock Units (RSUs) settled into 11,312 shares of Fortrea common stock as scheduled. To satisfy tax withholding obligations, 4,886 shares were sold on 08/19/2025 at a weighted average price of $8.01 per share. After these transactions the reporting person beneficially owned 54,770 shares of common stock and held 91,805 RSUs.
Positive
- Settlement of 11,312 RSUs into 11,312 shares on the scheduled vesting date
- Filing discloses weighted average sale price of $8.01 and price range ($7.89–$8.10), providing transaction transparency
Negative
- Issuer-mandated sell-to-cover resulted in the sale of 4,886 shares, reducing direct common stock holdings from 59,656 to 54,770
- Significant number of outstanding RSUs (91,805) remain unvested/convertible, representing potential future dilution
Insights
TL;DR: Routine executive equity vesting and mandated sell-to-cover tax sales; no discretionary trading or change in control signaled.
The Form 4 documents the scheduled settlement of 11,312 RSUs into common stock and a subsequent issuer-mandated sell-to-cover of 4,886 shares at a weighted average price of $8.01. These actions reflect compensation vesting mechanics and tax withholding procedures rather than an opportunistic disposition. The reporting person retains 54,770 shares and continues to hold 91,805 RSUs, indicating continued equity exposure to the company.
TL;DR: Disclosure is consistent with standard equity compensation administration and includes required explanatory detail.
The filing explains conversion of Labcorp-granted RSUs following Fortrea's spin-off and confirms the sales were mandatory to satisfy tax withholding under company plans. The form includes price ranges ($7.89–$8.10) and the weighted average sale price ($8.01), and is signed by an attorney-in-fact, meeting procedural requirements for Section 16 reporting. No departures, grants beyond the vesting, or discretionary sales are reported.